Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
Some studies have shown greater weight loss with Tirzepatide compared to semaglutide
In August 2025, the FDA approved semaglutide (Wegovy) for MASH with fibrosis, the first GLP-1 licensed for this indication
At baseline, eGFR was 90 mL/min/1.73 m2 in 43%, 60 to 90 mL/min/1.73 m2 in 40%, 45 to 60 mL/min/1.73 m2 in 10%, and 30 to 45 mL/min/1.73 m2 in 6% of patients
Your doctor must assess your individual medical situation, review your blood glucose patterns, and adjust dosages as needed
US$ 22.64
US$ 28.87
US$ 20.50
US$ 22.55
US$ 24.55
US$ 21.69
/https%3A%2F%2Fopengraph.b-cdn.net%2Fproduction%2Fimages%2F2ed46913-f157-43c3-9418-19fea49af16c.png%3Ftoken%3DUl4O1QAtXTaMUjOfpBooUL-C8jajM-YwYFPrjCtr6ms%26height%3D1080%26width%3D1080%26expires%3D33315971423/og.png)
US$ 22.26
US$ 27.05
US$ 22.86
